Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00969865 · ClinicalTrials.gov registry record
Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program
A clinical trial of Atherosclerosis, sponsored by Piedmont Healthcare.
- Completed
- Registry status
- 170
- Enrollment target
- 1
- Study location
NCT00969865 is a study of Atherosclerosis that has completed, run by Piedmont Healthcare. The registered enrollment target is 170 participants, below the 1,063-participant average among 69 other Atherosclerosis trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00969865, a study of Atherosclerosis, has completed, sponsored by Piedmont Healthcare.
- COMPLETED
- Registry status
- 170 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effectiveness of an individualized approach to diagnosing and/or treating atherosclerosis. This will be done by combining genetic information, lifestyle information, participant education, and imaging tests to track diagnoses, therapies, and treatment on two groups: 1) Standard Management Group (diagnosed and/or treated according to standard of care) and 2) Individualized Management Group (standard of care plus genetic testing and coronary artery calcium scans).
Conditions Studied
Study Locations (1)
Georgia
- Piedmont Heart Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2011-10 |
| Est. Completion | 2016-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00969865
The ClinicalTrials.gov registry entry for NCT00969865 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,063-participant average among 69 other Atherosclerosis trials with a reported enrollment target (84% lower). The listed sponsor is Piedmont Healthcare, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atherosclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT00969865 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT00969865 about?
NCT00969865 is a clinical study titled "Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program". This study will evaluate the effectiveness of an individualized approach to diagnosing and/or treating atherosclerosis. This will be done by combining genetic information, lifestyle information, participant education, and imaging tests to track diagnoses, therapies, and treatment on two groups: 1) S...
What is the current status of trial NCT00969865?
This trial is currently completed. The enrollment target is 170 participants. The study started on 2011-10. Estimated completion is 2016-12.
What conditions does trial NCT00969865 study?
This clinical trial studies the following conditions: Atherosclerosis.
Who is sponsoring clinical trial NCT00969865?
This trial is sponsored by Piedmont Healthcare, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00969865 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
RECRUITING · Phase 4
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
RECRUITING
-
New Heart Imaging Techniques to Evaluate Possible Heart Disease
RECRUITING · NA
-
Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.